Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man

Author： Hendriks Rudi W   Bredius Robbert GM   Pike-Overzet Karin   Staal Frank JT  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.15, Iss.8, 2011-08, pp. : 1003-1021

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel Treatment Options of Binge Eating Disorder

By  

Current Medicinal Chemistry, Vol. 18, Iss. 33, 2011-11 ,pp. : 5159-5164

Bentham Science Publishers

Access to resources Recommend Favorite

Novel Treatment Options for Inflammatory Bowel Disease: Targeting α4 Integrin

By Lanzarotto Francesco   Carpani Marta   Chaudhary Rakesh   Ghosh Subrata  

Drugs, Vol. 66, Iss. 9, 2006-01 ,pp. : 1179-1189

Adis International

Access to resources Recommend Favorite

Cell Death Mechanisms in Stroke and Novel Molecular and Cellular Treatment Options

By  

Current Neuropharmacology, Vol. 16, Iss. 9, 2018-11 ,pp. : 1396-1415

Bentham Science Publishers

Access to resources Recommend Favorite

Intravenous Immunoglobulin Replacement Therapy in the Treatment of Patients with Common Variable Immunodeficiency Disease: An Open-Label Prospective Study

By Kasztalska Karolina  

Clinical Drug Investigation, Vol. 31, Iss. 5, 2011-05 ,pp. : 299-307

Adis International

Access to resources Recommend Favorite

Therapeutic Strategies in Common Variable Immunodeficiency

By Sewell W.A.C.  

Drugs, Vol. 63, Iss. 13, 2003-01 ,pp. : 1359-1371

Adis International

Access to resources Recommend Favorite